Restarting production at the former Ben Venue facility in Ohio will be a “significant task” says Xellia Pharmaceuticals which plans to invest after buying the site from Hikma.
The huge former Ben Venue injectables manufacturing plant in Ohio that became the center of controversy over drug shortages a few years ago remains off line, and the company that now owns the site reiterated this week that it has no plans to resume making...
Hikma has bought defunct manufacturer Ben Venue and says it could reactivate the site in the long-term, despite the transfer of equipment across its sterile injectables network.
Outsourcing is still a significant part of Janssen’s strategy, the firm says despite suffering shortages due to manufacturing and quality problems at now defunct CMO Ben Venue.
Boehringer Ingelheim (BI) has warned that latest efforts to ensure continued Doxil production at Ben Venue's troubled sterile injectables plant in Bedford, Ohio must still be approved.
Ben Venue’s closure is still being evaluated the troubled drugmaker says, in the week the European Medicines Agency (EMA) is meeting to discuss ongoing shortages.
Beleaguered sterile injectables manufacturer Ben Venue Laboratories has announced it will close permanently by the end of 2013 and lay off 1,100 employees in Ohio.
Continued manufacturing problems at CMO Ben Venue Laboratories will cause an interruption of supplies of the cancer treatment Doxil in mid-to-late October, Janssen said.
US CMO Ben Venue has restarted 'limited drug manufacturing' at its plant in Bedford, Ohio, but does not expect to start shipping product for several months.
More bad news for troubled CMO Ben Venue Laboratories after European regulators recommend that production of two more drugs – Caelyx and Ceplene – is relocated to other facilities.
Ben Venue Laboratories will not restart manufacturing at its plant in Bedford, Ohio until later this quarter – at the earliest - after extending the voluntary suspension it implemented in November.
